Skip to main content

Table 3 Regional sero-prevalence (ages 2–10 years) by antigen and all-age incidence rates for clinical malaria and Pf infection. Mean sero-prevalence (%) and incidence rates with 95% CI shown in parentheses

From: Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia

  West Coast Region (WCR) Upper River Region (URR)
July 2013 December 2013 July 2013 December 2013
Clinical incidence rate 0.08 (0.04–0.21) 0.14 (0.04–0.44) 0.13 (0.04–0.39) 0.21 (0.1–0.51)
Pf infection rate 0.23 (0.13–0.39) 0.67 (0.40–1.13) 0.56 (0.42–0.74) 2.87 (2.36–3.50)
Sero-prevalence (ages 2–10 years)
  n = 205 n = 197 n = 275 n = 324
Etramp5.Ag1 4.4% (1.6–7.2) 13.7% (8.9–18.5) 8.7% (5.4–12.1) 33.3% (27.4–39.3)
GEXP18 11.7% (7.3–16.1) 12.7% (8.0–17.3) 25.1% (20.0–30.2) 36.3% (30.2–42.3)
HSP40.Ag1 5.4% (2.3–8.5) 6.1% (2.8–9.4) 8.4% (5.1–11.6) 23.8% (18.4–29.1)
Rh2.2030 1.0% (0.0–2.3) 1.0% (0.0–2.4) 9.8% (6.3–13.3) 25.4% (19.9–30.9)
EBA175 1.5% (0.0–3.1) 1.0% (0.0–2.4) 7.3% (4.2–10.3) 15.8% (11.2–20.5)
PfMSP119 2.9% (0.6–5.2) 8.1% (4.3–11.9) 5.1% (2.5–7.7) 22.1% (16.8–27.3)
PfAMA1 4.4% (1.6–7.2) 4.1% (1.3–6.8) 17.8% (13.3–22.3) 33.3% (27.4–39.3)
PfGLURP.R2 4.4% (1.6–7.2) 8.1% (4.3–11.9) 16.4% (12.0–20.7) 30.4% (24.6–36.2)